#United States #Seattle #Clinical Trials #Atossa Therapeutics #Z-Endoxifen

Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results

Atossa Therapeutics, Inc. (Nasdaq: ATOS) has recently shared its financial outcomes for the fourth quarter of 2025 and provided a comprehensive update on its corporate activities. The company focuses on developing innovative therapies specifically targeting oncology and other critical clinical needs, highlighting its pivotal journey towards more effective medical solutions.

Dr. Steven Quay, the President and CEO of Atossa, emphasized the meaningful strides made in the development of (Z)-endoxifen, focusing on its applications in oncology, while also investigating its relevance in rare diseases such as Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS). Dr. Quay remarked, "The past year has shown us plenty of opportunities to leverage our technology to address urgent health conditions."

Financial Performance Overview

In the fiscal year ending December 31, 2025, Atossa’s total operational expenses rose to $37.1 million, an increase from $27.6 million in 2024. Notably, the company's research and development expenses accounted for a significant portion of this rise, driven primarily by enhanced spending on clinical and non-clinical trials related to (Z)-endoxifen. The company recorded an increase in clinical trial expenditures of 60% year-over-year, reflecting robust investments in the trial processes and drug development costs.

Furthermore, Atossa’s general and administrative expenses also saw a surge, amounting to $15.9 million, compared to $13.5 million in the previous year. This increase was attributed to higher legal fees and added costs concerning ongoing litigation and patent defense.

Advancements in Drug Development

Atossa's efforts in advancing rare diseases were underscored by the FDA granting both Rare Pediatric Disease and Orphan Drug designations to (Z)-endoxifen in 2025 for the treatment of DMD. This designation allows for potential speed in the FDA review process while affording financial advantages for the development of the therapy. Dr. Quay noted, "The remarkable ability of (Z)-endoxifen to possibly mitigate multiple disease-driving factors in DMD positions us uniquely in the treatment landscape."

Recognized for its innovative work, Atossa won the prestigious 2025 Clinical Trials Arena Research and Development Excellence Award in the Precision Endocrine Therapy category, acknowledging its groundbreaking approaches in oncology treatment strategies.

Corporate Structuring and Team Expansion

In line with its growth strategy, Atossa has expanded its clinical leadership team by bringing on board seasoned biopharma veterans such as Dr. Kathy Puyana Theall and Dr. Adebola Giwa. Their expertise in breast oncology and rare diseases respectively, is expected to bolster the direction of Atossa’s (Z)-endoxifen programs. Dr. Quay expressed confidence in this new addition saying, "With strengthened leadership, we are even better poised to execute our developmental strategies efficiently."

Moving forward, Atossa is looking to align its strategic resources efficiently with an eye on potential commercialization. The company has adopted a clear vision focused on advancing their clinical programs to meet critical milestones while ensuring a strong balance sheet.

Future Directions and Considerations

Looking ahead, Atossa plans to continue its focused strategy on (Z)-endoxifen and its indications. The company believes its unique pharmacological properties will help address various health complications atypical to traditional therapies. Atossa aims to make significant breakthroughs in the areas of oncology and rare diseases, making strides towards market presence in the biopharmaceutical industry.

As Atossa therapeutics continues its developmental journey, its commitment to addressing significant unmet needs in healthcare remains unwavering. Investors and stakeholders can follow their progress as they navigate the complexities of clinical trials and regulatory approvals, setting the stage for a transformative impact in biopharmaceutical innovation.